成纤维细胞激活蛋白靶向光动力治疗小鼠胰腺导管腺癌模型中癌症相关成纤维细胞的研究

IF 4.5 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Daphne N. Dorst, Esther M. M. Smeets, Christian Klein, Cathelijne Frielink, Daan Geijs, Marija Trajkovic-Arsic, Phyllis F. Y. Cheung, Martijn W. J. Stommel, Martin Gotthardt, Jens T. Siveke, Erik H. J. G. Aarntzen and Sanne A. M. van Lith*, 
{"title":"成纤维细胞激活蛋白靶向光动力治疗小鼠胰腺导管腺癌模型中癌症相关成纤维细胞的研究","authors":"Daphne N. Dorst,&nbsp;Esther M. M. Smeets,&nbsp;Christian Klein,&nbsp;Cathelijne Frielink,&nbsp;Daan Geijs,&nbsp;Marija Trajkovic-Arsic,&nbsp;Phyllis F. Y. Cheung,&nbsp;Martijn W. J. Stommel,&nbsp;Martin Gotthardt,&nbsp;Jens T. Siveke,&nbsp;Erik H. J. G. Aarntzen and Sanne A. M. van Lith*,&nbsp;","doi":"10.1021/acs.molpharmaceut.3c00453","DOIUrl":null,"url":null,"abstract":"<p >Patients with pancreatic ductal adenocarcinoma (PDAC) have a dismal 5 year survival of 9%. One important limiting factor for treatment efficacy is the dense tumor-supporting stroma. The cancer-associated fibroblasts in this stroma deposit excessive amounts of extracellular matrix components and anti-inflammatory mediators, which hampers the efficacy of chemo- and immunotherapies. Systemic depletion of all activated fibroblasts is, however, not feasible nor desirable and therefore a local approach should be pursued. Here, we provide a proof-of-principle of using fibroblast activation protein (FAP)-targeted photodynamic therapy (tPDT) to treat PDAC. FAP-targeting antibody 28H1 and irrelevant control antibody DP47GS were conjugated to the photosensitizer IRDye700DX (700DX) and the chelator diethylenetriaminepentaacetic acid. In vitro binding and cytotoxicity were evaluated using the fibroblast cell-line NIH-3T3 stably transfected with FAP. Biodistribution of <sup>111</sup>In-labeled antibody-700DX constructs was determined in mice carrying syngeneic tumors of the murine PDAC cell line PDAC299, and in a genetically engineered PDAC mouse model (<i>CKP</i>). Then, tPDT was performed by exposing the subcutaneous or the spontaneous PDAC tumors to 690 nm light. Induction of apoptosis after treatment was assessed using automated analyses of immunohistochemistry for cleaved caspase-3. 28H1-700DX effectively bound to 3T3-FAP cells and induced cytotoxicity upon exposure to 690 nm light, whereas no binding or cytotoxic effects were observed for DP47GS-700DX. Although both 28H1-700DX and DP47GS-700DX accumulated in subcutaneous PDAC299 tumors, autoradiography demonstrated that only 28H1-700DX reached the tumor core. On the contrary, control antibody DP47GS-700DX was only present at the tumor rim. In <i>CKP</i> mice, both antibodies accumulated in the tumor, but tumor-to-blood ratios of 28H1-700DX were higher than that of the control. Notably, in vivo FAP-tPDT caused upregulation of cleaved caspase-3 staining in both subcutaneous and in spontaneous tumors. In conclusion, we have shown that tPDT is a feasible approach for local depletion of FAP-expressing stromal cells in murine models for PDAC.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"20 8","pages":"4319–4330"},"PeriodicalIF":4.5000,"publicationDate":"2023-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acs.molpharmaceut.3c00453","citationCount":"0","resultStr":"{\"title\":\"Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma\",\"authors\":\"Daphne N. Dorst,&nbsp;Esther M. M. Smeets,&nbsp;Christian Klein,&nbsp;Cathelijne Frielink,&nbsp;Daan Geijs,&nbsp;Marija Trajkovic-Arsic,&nbsp;Phyllis F. Y. Cheung,&nbsp;Martijn W. J. Stommel,&nbsp;Martin Gotthardt,&nbsp;Jens T. Siveke,&nbsp;Erik H. J. G. Aarntzen and Sanne A. M. van Lith*,&nbsp;\",\"doi\":\"10.1021/acs.molpharmaceut.3c00453\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Patients with pancreatic ductal adenocarcinoma (PDAC) have a dismal 5 year survival of 9%. One important limiting factor for treatment efficacy is the dense tumor-supporting stroma. The cancer-associated fibroblasts in this stroma deposit excessive amounts of extracellular matrix components and anti-inflammatory mediators, which hampers the efficacy of chemo- and immunotherapies. Systemic depletion of all activated fibroblasts is, however, not feasible nor desirable and therefore a local approach should be pursued. Here, we provide a proof-of-principle of using fibroblast activation protein (FAP)-targeted photodynamic therapy (tPDT) to treat PDAC. FAP-targeting antibody 28H1 and irrelevant control antibody DP47GS were conjugated to the photosensitizer IRDye700DX (700DX) and the chelator diethylenetriaminepentaacetic acid. In vitro binding and cytotoxicity were evaluated using the fibroblast cell-line NIH-3T3 stably transfected with FAP. Biodistribution of <sup>111</sup>In-labeled antibody-700DX constructs was determined in mice carrying syngeneic tumors of the murine PDAC cell line PDAC299, and in a genetically engineered PDAC mouse model (<i>CKP</i>). Then, tPDT was performed by exposing the subcutaneous or the spontaneous PDAC tumors to 690 nm light. Induction of apoptosis after treatment was assessed using automated analyses of immunohistochemistry for cleaved caspase-3. 28H1-700DX effectively bound to 3T3-FAP cells and induced cytotoxicity upon exposure to 690 nm light, whereas no binding or cytotoxic effects were observed for DP47GS-700DX. Although both 28H1-700DX and DP47GS-700DX accumulated in subcutaneous PDAC299 tumors, autoradiography demonstrated that only 28H1-700DX reached the tumor core. On the contrary, control antibody DP47GS-700DX was only present at the tumor rim. In <i>CKP</i> mice, both antibodies accumulated in the tumor, but tumor-to-blood ratios of 28H1-700DX were higher than that of the control. Notably, in vivo FAP-tPDT caused upregulation of cleaved caspase-3 staining in both subcutaneous and in spontaneous tumors. In conclusion, we have shown that tPDT is a feasible approach for local depletion of FAP-expressing stromal cells in murine models for PDAC.</p>\",\"PeriodicalId\":52,\"journal\":{\"name\":\"Molecular Pharmaceutics\",\"volume\":\"20 8\",\"pages\":\"4319–4330\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2023-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://pubs.acs.org/doi/epdf/10.1021/acs.molpharmaceut.3c00453\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Pharmaceutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.3c00453\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.3c00453","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

胰腺导管腺癌(PDAC)患者的5年生存率为9%,令人沮丧。治疗效果的一个重要限制因素是肿瘤支持基质的致密性。这种基质中的癌症相关成纤维细胞沉积了过量的细胞外基质成分和抗炎介质,这阻碍了化疗和免疫治疗的疗效。然而,所有活化的成纤维细胞的系统消耗是不可行的,也不可取的,因此应采取局部方法。在这里,我们提供了使用成纤维细胞激活蛋白(FAP)靶向光动力疗法(tPDT)治疗PDAC的原理证明。将fap靶向抗体28H1和不相关对照抗体DP47GS与光敏剂IRDye700DX (700DX)和螯合剂二乙烯三胺五乙酸偶联。采用稳定转染FAP的成纤维细胞系NIH-3T3进行体外结合和细胞毒性评价。在携带PDAC细胞系PDAC299同源肿瘤的小鼠和基因工程PDAC小鼠模型(CKP)中,测定了111in标记的抗体700dx构建物的生物分布。然后,将皮下或自发PDAC肿瘤暴露在690 nm光下进行tPDT。使用免疫组织化学自动分析裂解caspase-3来评估治疗后诱导的细胞凋亡。28H1-700DX能有效结合3T3-FAP细胞,并在690 nm光下诱导细胞毒性,而DP47GS-700DX没有结合或细胞毒性作用。虽然28H1-700DX和DP47GS-700DX在皮下PDAC299肿瘤中均有积累,但放射自显像显示只有28H1-700DX到达肿瘤核心。相反,对照抗体DP47GS-700DX仅在肿瘤边缘存在。在CKP小鼠中,这两种抗体都在肿瘤中积累,但28H1-700DX的肿瘤与血液比率高于对照组。值得注意的是,体内FAP-tPDT在皮下和自发肿瘤中引起cleaved caspase-3染色上调。总之,我们已经证明tPDT是PDAC小鼠模型中表达fap的基质细胞局部耗竭的可行方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma

Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma

Patients with pancreatic ductal adenocarcinoma (PDAC) have a dismal 5 year survival of 9%. One important limiting factor for treatment efficacy is the dense tumor-supporting stroma. The cancer-associated fibroblasts in this stroma deposit excessive amounts of extracellular matrix components and anti-inflammatory mediators, which hampers the efficacy of chemo- and immunotherapies. Systemic depletion of all activated fibroblasts is, however, not feasible nor desirable and therefore a local approach should be pursued. Here, we provide a proof-of-principle of using fibroblast activation protein (FAP)-targeted photodynamic therapy (tPDT) to treat PDAC. FAP-targeting antibody 28H1 and irrelevant control antibody DP47GS were conjugated to the photosensitizer IRDye700DX (700DX) and the chelator diethylenetriaminepentaacetic acid. In vitro binding and cytotoxicity were evaluated using the fibroblast cell-line NIH-3T3 stably transfected with FAP. Biodistribution of 111In-labeled antibody-700DX constructs was determined in mice carrying syngeneic tumors of the murine PDAC cell line PDAC299, and in a genetically engineered PDAC mouse model (CKP). Then, tPDT was performed by exposing the subcutaneous or the spontaneous PDAC tumors to 690 nm light. Induction of apoptosis after treatment was assessed using automated analyses of immunohistochemistry for cleaved caspase-3. 28H1-700DX effectively bound to 3T3-FAP cells and induced cytotoxicity upon exposure to 690 nm light, whereas no binding or cytotoxic effects were observed for DP47GS-700DX. Although both 28H1-700DX and DP47GS-700DX accumulated in subcutaneous PDAC299 tumors, autoradiography demonstrated that only 28H1-700DX reached the tumor core. On the contrary, control antibody DP47GS-700DX was only present at the tumor rim. In CKP mice, both antibodies accumulated in the tumor, but tumor-to-blood ratios of 28H1-700DX were higher than that of the control. Notably, in vivo FAP-tPDT caused upregulation of cleaved caspase-3 staining in both subcutaneous and in spontaneous tumors. In conclusion, we have shown that tPDT is a feasible approach for local depletion of FAP-expressing stromal cells in murine models for PDAC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Molecular Pharmaceutics
Molecular Pharmaceutics 医学-药学
CiteScore
8.00
自引率
6.10%
发文量
391
审稿时长
2 months
期刊介绍: Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development. Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信